Sign in or create an account to add this stock to your watchlist.
About Seres Therapeutics (NASDAQ:MCRB)
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company is also developing SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. In addition, its product candidates in pre-clinical development comprise SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; SER-401 for use with checkpoint inhibitors in patients with solid tumors; and SER-155, an Ecobiotic microbiome therapeutic candidate for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MCRB
CUSIPN/A
Phone617-945-9626
Debt
Debt-to-Equity Ratio0.85
Current Ratio3.60
Quick Ratio3.60
Price-To-Earnings
Trailing P/E Ratio-3.67
Forward P/E Ratio-3.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$32.10 million
Price / Sales10.27
Cash FlowN/A
Price / CashN/A
Book Value$0.25 per share
Price / Book32.44
Profitability
EPS (Most Recent Fiscal Year)($2.21)
Net Income$-89,380,000.00
Net Margins-277.79%
Return on Equity-150.44%
Return on Assets-47.26%
Miscellaneous
Employees138
Outstanding Shares40,650,000
Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions
What is Seres Therapeutics' stock symbol?
Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."
How were Seres Therapeutics' earnings last quarter?
Seres Therapeutics (NASDAQ:MCRB) released its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.06. The biotechnology company had revenue of $3.97 million for the quarter, compared to analyst estimates of $3 million. Seres Therapeutics had a negative return on equity of 150.44% and a negative net margin of 277.79%. View Seres Therapeutics' Earnings History.
When is Seres Therapeutics' next earnings date?
What price target have analysts set for MCRB?
8 Wall Street analysts have issued twelve-month price objectives for Seres Therapeutics' stock. Their predictions range from $19.00 to $20.00. On average, they expect Seres Therapeutics' share price to reach $19.3333 in the next twelve months. View Analyst Ratings for Seres Therapeutics.
Who are some of Seres Therapeutics' key competitors?
Some companies that are related to Seres Therapeutics include Biohaven Pharmaceutical (BHVN), Amneal Pharmaceuticals (AMRX), Immuron (IMRN), Myovant Sciences (MYOV), Theravance Biopharma (TBPH), WAVE Life Sciences (WVE), Epizyme (EPZM), Intra-Cellular Therapies (ITCI), Uniqure (QURE), Retrophin (RTRX), Revance Therapeutics (RVNC), Apellis Pharmaceuticals (APLS), Mirati Therapeutics (MRTX), Athenex (ATNX) and Esperion Therapeutics (ESPR).
Who are Seres Therapeutics' key executives?
Seres Therapeutics' management team includes the folowing people:
- Dr. Roger James Pomerantz, Chairman, Pres & CEO (Age 61)
- Dr. Noubar B. Afeyan Ph.D., Co-Founder & Lead Independent Director (Age 55)
- Mr. Thomas J. DesRosier, Chief Legal Officer, Exec. VP & Sec. (Age 63)
- Mr. Eric D. Shaff, COO, CFO, Exec. VP & Principal Accounting Officer (Age 42)
- Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 57)
When did Seres Therapeutics IPO?
(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.
Has Seres Therapeutics been receiving favorable news coverage?
Press coverage about MCRB stock has been trending somewhat positive recently, according to Accern. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Seres Therapeutics earned a news sentiment score of 0.15 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 47.21 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Seres Therapeutics' major shareholders?
Seres Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include NESTLE HEALTH SCIENCE US HOLDINGS, INC. (16.97%), BlackRock Inc. (4.48%), Federated Investors Inc. PA (4.35%), JPMorgan Chase & Co. (1.04%), Millennium Management LLC (0.21%) and Spark Investment Management LLC (0.20%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship. View Institutional Ownership Trends for Seres Therapeutics.
Which institutional investors are selling Seres Therapeutics stock?
MCRB stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co. and BlackRock Inc.. Company insiders that have sold Seres Therapeutics company stock in the last year include David N Cook, John G Aunins and Roger Pomerantz. View Insider Buying and Selling for Seres Therapeutics.
Which institutional investors are buying Seres Therapeutics stock?
How do I buy shares of Seres Therapeutics?
Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seres Therapeutics' stock price today?
One share of MCRB stock can currently be purchased for approximately $8.11.
How big of a company is Seres Therapeutics?
Seres Therapeutics has a market capitalization of $324.41 million and generates $32.10 million in revenue each year. The biotechnology company earns $-89,380,000.00 in net income (profit) each year or ($2.21) on an earnings per share basis. Seres Therapeutics employs 138 workers across the globe.
How can I contact Seres Therapeutics?
Seres Therapeutics' mailing address is 200 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626.
MarketBeat Community Rating for Seres Therapeutics (MCRB)
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Seres Therapeutics (NASDAQ:MCRB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Seres Therapeutics in the last 12 months. Their average twelve-month price target is $19.3333, suggesting that the stock has a possible upside of 138.39%. The high price target for MCRB is $20.00 and the low price target for MCRB is $19.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.3333 | $18.8571 | $18.75 | $18.75 |
| Price Target Upside: | 138.39% upside | 73.48% upside | 72.49% upside | 72.49% upside |
Seres Therapeutics (NASDAQ:MCRB) Consensus Price Target History
Seres Therapeutics (NASDAQ:MCRB) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Seres Therapeutics (NASDAQ:MCRB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Seres Therapeutics (NASDAQ MCRB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 41.90%
Institutional Ownership Percentage: 79.54%
Seres Therapeutics (NASDAQ MCRB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/9/2018 | Roger Pomerantz | Insider | Sell | 233 | $9.00 | $2,097.00 | |  |
| 4/25/2018 | John G Aunins | Insider | Sell | 14,279 | $7.58 | $108,234.82 | 184,485 | |
| 1/26/2018 | David N Cook | Insider | Sell | 1,738 | $11.02 | $19,152.76 | 141,673 | |
| 12/19/2017 | John G Aunins | Insider | Sell | 1,623 | $10.14 | $16,457.22 | 61,060 | |
| 8/29/2016 | John G Aunins | Insider | Sell | 9,390 | $10.87 | $102,069.30 | 192,125 | |
| 7/28/2016 | Michele Trucksis | Insider | Sell | 4,156 | $35.18 | $146,208.08 | 4,156 | |
| 7/27/2016 | Michele Trucksis | Insider | Sell | 38,064 | $35.14 | $1,337,568.96 | 38,064 | |
| 7/25/2016 | John G Aunins | Insider | Sell | 9,390 | $34.18 | $320,950.20 | 220,155 | |
| 7/6/2016 | Roger Pomerantz | CEO | Sell | 88,211 | $29.45 | $2,597,813.95 | 236,468 | |
| 7/1/2016 | Roger Pomerantz | CEO | Sell | 56,789 | $29.81 | $1,692,880.09 | 240,481 | |
| 6/30/2016 | Eric D Shaff | CFO | Sell | 4,533 | $29.54 | $133,904.82 | 4,533 | |
| 6/28/2016 | Eric D Shaff | CFO | Sell | 5,001 | $28.28 | $141,428.28 | 3,334 | |
| 6/27/2016 | John G Aunins | EVP | Sell | 9,390 | $27.23 | $255,689.70 | 32,655 | |
| 6/2/2016 | David N Cook | EVP | Sell | 8,000 | $31.00 | $248,000.00 | 136,673 | |
| 6/2/2016 | Roger Pomerantz | CEO | Sell | 74,049 | $32.52 | $2,408,073.48 | 257,741 | |
| 6/1/2016 | David N Cook | EVP | Sell | 16,000 | $29.43 | $470,880.00 | 144,673 | |
| 6/1/2016 | Roger Pomerantz | CEO | Sell | 70,951 | $30.51 | $2,164,715.01 | 254,643 | |
| 5/25/2016 | Ventures Fund 2007 L Flagship | Major Shareholder | Sell | 1,000,000 | $27.60 | $27,600,000.00 | | |
| 5/24/2016 | Roger Pomerantz | CEO | Sell | 9,801 | $30.00 | $294,030.00 | 193,493 | |
| 5/6/2016 | Roger Pomerantz | CEO | Sell | 8,507 | $24.31 | $206,805.17 | 31,234 | |
| 5/5/2016 | Roger Pomerantz | CEO | Sell | 59,325 | $26.13 | $1,550,162.25 | 51,325 | |
| 5/3/2016 | Roger Pomerantz | CEO | Sell | 67,367 | $28.70 | $1,933,432.90 | 66,414 | |
| 4/25/2016 | John G Aunins | EVP | Sell | 18,640 | $31.94 | $595,361.60 | 56,060 | |
| 4/7/2016 | David N Cook | EVP | Sell | 8,000 | $31.00 | $248,000.00 | 160,673 | |
| 4/7/2016 | Roger Pomerantz | CEO | Sell | 9,212 | $30.00 | $276,360.00 | 24,439 | |
| 4/4/2016 | David N Cook | EVP | Sell | 61,000 | $26.16 | $1,595,760.00 | 183,023 | |
| 4/4/2016 | Eric D Shaff | CFO | Sell | 6,568 | $28.85 | $189,486.80 | 6,568 | |
| 4/4/2016 | Roger Pomerantz | CEO | Sell | 135,788 | $27.20 | $3,693,433.60 | 113,690 | |
| 3/31/2016 | Eric D Shaff | CFO | Sell | 7,663 | $26.30 | $201,536.90 | 7,663 | |
| 3/28/2016 | Eric D Shaff | CFO | Sell | 5,473 | $24.07 | $131,735.11 | 5,473 | |
| 3/28/2016 | John G Aunins | EVP | Sell | 9,390 | $23.89 | $224,327.10 | 74,700 | |
(Data available from 1/1/2013 forward)
Seres Therapeutics (NASDAQ MCRB) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Brokers Issue Forecasts for Seres Therapeutics' Q2 2018 Earnings (MCRB)
www.americanbankingnews.com - May 21 at 1:06 AM |
| Seres Therapeutics (MCRB) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 20 at 1:34 AM |
 | Seres Therapeutics (MCRB) Presents At Bank of America Merrill Lynch 2018 Healthcare Conference - Slideshow
seekingalpha.com - May 18 at 6:07 PM |
 | Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018
finance.yahoo.com - May 17 at 8:14 AM |
| Seres Therapeutics (MCRB) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:21 PM |
| Q2 2018 EPS Estimates for Seres Therapeutics (MCRB) Raised by Analyst
www.americanbankingnews.com - May 14 at 2:14 AM |
| Seres Therapeutics' (MCRB) CEO Roger Pomerantz on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 8:14 AM |
| Seres Therapeutics (MCRB) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 12 at 10:38 AM |
| Seres Therapeutics (MCRB) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - May 10 at 8:29 PM |
| Edited Transcript of MCRB earnings conference call or presentation 9-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 6:05 PM |
| Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates
finance.yahoo.com - May 9 at 8:12 AM |
| Seres Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:12 AM |
| Seres Therapeutics to Present at Two Upcoming May Conferences
finance.yahoo.com - May 4 at 8:13 AM |
| Seres Therapeutics Inc (MCRB) Insider Sells $108,234.82 in Stock
www.americanbankingnews.com - April 26 at 7:30 PM |
| Seres Therapeutics (MCRB) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - April 25 at 7:33 AM |
| Seres Therapeutics Inc (MCRB) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 25 at 1:52 AM |
| Seres Therapeutics (MCRB) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 19 at 8:31 PM |
| Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 17 at 6:03 PM |
| Seres Therapeutics (MCRB) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - April 16 at 9:16 AM |
| Seres Therapeutics (MCRB) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 14 at 8:35 PM |
| Seres Therapeutics (MCRB) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - April 13 at 11:03 AM |
| Seres Therapeutics (MCRB) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 12 at 10:46 PM |
| $3.00 Million in Sales Expected for Seres Therapeutics Inc (MCRB) This Quarter
www.americanbankingnews.com - April 12 at 5:05 AM |
| Seres Therapeutics Inc (MCRB) Expected to Announce Earnings of -$0.74 Per Share
www.americanbankingnews.com - April 10 at 3:13 AM |
 | Seres Therapeutics wins dismissal of investor lawsuit over drug study
www.reuters.com - April 3 at 5:40 PM |
| Seres Therapeutics Inc (MCRB) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 31 at 1:36 AM |
| Zacks Investment Research Lowers Seres Therapeutics (MCRB) to Hold
www.americanbankingnews.com - March 30 at 10:02 PM |
| Seres Therapeutics (MCRB) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - March 28 at 10:44 AM |
| Zacks: Brokerages Expect Seres Therapeutics Inc (MCRB) Will Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - March 26 at 8:04 AM |
| BidaskClub Lowers Seres Therapeutics (MCRB) to Sell
www.americanbankingnews.com - March 25 at 9:51 AM |
| Edited Transcript of MCRB earnings conference call or presentation 8-Mar-18 1:00pm GMT
finance.yahoo.com - March 18 at 6:27 PM |
| Zacks Investment Research Upgrades Seres Therapeutics (MCRB) to "Hold"
www.americanbankingnews.com - March 18 at 10:32 AM |
| FY2018 EPS Estimates for Seres Therapeutics Inc (MCRB) Lifted by Cantor Fitzgerald
www.americanbankingnews.com - March 14 at 10:28 AM |
| Research Analysts Issue Forecasts for Seres Therapeutics Inc's FY2019 Earnings (MCRB)
www.americanbankingnews.com - March 13 at 3:07 PM |
| Seres Therapeutics (MCRB) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 11 at 2:07 PM |
| Seres Therapeutics (MCRB) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - March 10 at 5:28 PM |
| Seres Therapeutics (MCRB) Releases Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - March 9 at 4:15 PM |
 | Seres Therapeutics to Present at Two Upcoming March Conferences - Business Wire (press release)
www.businesswire.com - March 9 at 8:12 AM |
| Seres Therapeutics to Present at Two Upcoming March Conferences
finance.yahoo.com - March 9 at 8:12 AM |
| Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates - Business Wire (press release)
www.businesswire.com - March 8 at 8:15 AM |
| Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
finance.yahoo.com - March 8 at 8:15 AM |
| Seres Therapeutics Inc to Host Earnings Call
finance.yahoo.com - March 8 at 8:15 AM |
| Seres Therapeutics Inc (MCRB) Expected to Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - March 8 at 2:02 AM |
| Seres Therapeutics (MCRB) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:50 AM |
| Seres Therapeutics Inc (MCRB) Expected to Announce Earnings of -$0.73 Per Share
www.americanbankingnews.com - March 6 at 9:22 PM |
| Seres Therapeutics Inc (MCRB) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 6 at 1:36 AM |
| Citadel Advisors LLC Buys New Position in Seres Therapeutics Inc (MCRB)
www.americanbankingnews.com - March 3 at 5:20 AM |
| Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and ... - Business Wire (press release)
www.businesswire.com - March 2 at 8:09 AM |
| Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018
finance.yahoo.com - March 2 at 8:09 AM |
| Report: Developing Opportunities within AeroVironment, Seres Therapeutics, HFF, Fluor, KB Home, and H. B. Fuller — Future Expectations, Projections Moving into 2018
finance.yahoo.com - February 26 at 8:11 AM |
Seres Therapeutics (NASDAQ:MCRB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Seres Therapeutics (NASDAQ:MCRB) Income Statement, Balance Sheet and Cash Flow Statement
Seres Therapeutics (NASDAQ MCRB) Stock Chart for Thursday, May, 24, 2018
Loading chart…
